Telix制药公司面临关于投资者误报前列腺癌药物进展的调查,这在证交会传票后引发了库存下降。 Telix Pharmaceuticals faces investigation over alleged investor misrepresentation on prostate cancer drug progress, triggering a stock drop after an SEC subpoena.

Rosen律师事务所正在调查Telix制药公司(TLX)在2025年7月22日美国证券交易委员会传票索取相关文件后, 误导投资者开发前列腺癌药物的指控。 The Rosen Law Firm is investigating Telix Pharmaceuticals (TLX) over allegations it misled investors about its prostate cancer drug development, following a July 22, 2025, SEC subpoena seeking related documents. Telix的股票次日下跌10.44%。 The next day, Telix’s stock dropped 10.44%. 在指称的误报期间购买TLX股票的投资者可能有资格根据应急费用安排提出不预付费用的集体诉讼。 Investors who bought TLX shares during the alleged misrepresentation period may qualify for a no-upfront-cost class action lawsuit under a contingency fee arrangement. 该公司以证券诉讼闻名,正在从受影响的股东那里收集信息。 The firm, known for securities litigation, is gathering information from affected shareholders.